RT期刊文章SR电子T1慢性咳嗽、慢性疼痛的相关性的摩根富林明欧洲呼吸杂志乔和J FD欧元欧洲呼吸学会SP 2002651 10.1183/13993003.02651 -2020 A1 Arinze, Johnmary t A1 Verhamme,凯蒂·m·c·A1卢伊克,安玛丽即188bet官网地址A1前锋,布鲁诺A1范·穆尔,乔伊斯·b·J . A1 Brusselle由于慢性咳嗽与慢性疼痛有共同的神经生物学机制和病理生理学，两种临床疾病可能是相关的。因此，我们在鹿特丹研究中研究了成人受试者慢性咳嗽和慢性疼痛之间的关系，鹿特丹研究是一项大型的基于人群的前瞻性队列研究。方法采用标准化调查问卷，将持续6个月以上的慢性疼痛分为每周/每月或每天疼痛的频率。慢性咳嗽被描述为每天咳嗽至少持续3个月。纵向和横断面的关联被双向调查。研究中7141名受试者中，54% (n=3888)报告基线时存在慢性疼痛。每日慢性疼痛和慢性咳嗽的共流行率为4.4%。与无慢性疼痛的受试者相比，慢性咳嗽在每日和每周/每月慢性疼痛的受试者中更为普遍(13.8%和10.3%对8.2%，p<0.001)。在校正了潜在混杂因素后，普遍的慢性疼痛与慢性咳嗽的发生率显著相关(OR 1.47, 95% CI 1.08-1.99)。在每日慢性疼痛的受试者中，这种关联仍然显著(OR 1.49, 95% CI 1.06-2.11)，而在每周/每月慢性疼痛的受试者中，这种关联虽然不显著，但效果估计类似(OR 1.43, 95% CI 0.98-2.10)。 After adjustment for covariables, subjects with chronic cough had a significant risk of developing chronic pain (OR 1.63, 95% CI 1.02–2.62) compared with those without chronic cough.Conclusion Chronic cough and chronic pain confer risk on each other among adult subjects, indicating that both conditions might share common risk factors and/or pathophysiologic mechanisms.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Arinze reports grants from MSD, outside the submitted work;.Conflict of interest: KV works for a research group who in the past received unconditional grants from Yamanouchi, Pfizer/Boehringer Ingelheim, Novartis, GSK none of which relate to the content of this work.Conflict of interest: Dr. Luik has nothing to disclose.Conflict of interest: Dr. Stricker has nothing to disclose.Conflict of interest: Dr. van Meurs has nothing to disclose.Conflict of interest: Dr. Brusselle reports personal fees from Astra Zeneca, personal fees from Boehringer-Ingelheim, personal fees from Chiesi, personal fees from Glaxo Smith Kline, personal fees from Novartis, personal fees from Sanofi, personal fees from Teva, grants from MSD, outside the submitted work;.